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The novel bisphosphonate (BP) disodium dihydrogen-4-[(methylthio) phenylthio] methanebi-
sphosphonate (MPMBP) is a non-nitrogen-containing BP with an antioxidant side chain that possesses
anti-inﬂammatory properties. We investigated the systemic effects of this compound on bone loss induced
by ovariectomy (OVX) in adult rats. Micro-computed tomography revealed that MPMBP increased bone
mass and density in both the metaphysis and diaphysis, and improved the structural properties important
for mechanical strength of osteoporotic bone. Sequential bone labeling with tetracycline and calcein
indicated that MPMBP decreased longitudinal growth of the primary spongiosa (PS), but stimulated
cortical bone formation in the diaphysis. MPMBP increased type I collagen accumulation in the PS, and
decreased the number and size of adipocytes in the bone marrow, suggesting inhibition of increased bone
marrow adipogenesis induced by OVX. Furthermore, MPMBP reduced the number of bone resorbing
cathepsin K-positive osteoclasts induced by OVX. These results suggest that MPMBP could improve bone
loss induced by estrogen deﬁciency. Both stimulation of bone formation and inhibition of bone resorption
might play a role in the increase in bone mass and bone density after MPMBP treatment.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Osteoporosis is a common disease characterized by a signiﬁcant
decrease in bone mass and deterioration of the skeletal architec-
ture, leading to an increased risk of fracture. Postmenopausal
osteoporosis is prevalent in more than 30% of postmenopausal fe-
males and is strongly associated with diminishing estrogen levels.rmacological Society.
, Department of Oral Medical
Tomitamachi-Aza Misumido,
g by Elsevier B.V. on behalf of Japa
d/4.0/).Decreased estrogen levels affect the differentiation and function of
osteoblasts and osteoclasts, leading to an increase in the activation
frequency rate and an imbalance between bone formation and
resorption (1).
Bisphosphonates (BPs) are synthetic compounds characterized
by a PeCeP bond instead of the PeOeP bond of pyrophosphates.
They exhibit a high afﬁnity for hydroxyapatite crystals and strongly
suppress osteoclastic bone resorption (2), however their pharma-
cological characteristics, such as potency and side effects, vary
depending on the nature of their side chains (3,4).
The novel BP disodium dihydrogen-4-[(methylthio) phenylthio]
methanebisphosphonate (MPMBP) is a non-nitrogen-containing BP
with an antioxidant methylthio-phenylthio side chain (Fig. 1).
Previous studies suggest that MPMBP inhibits both bone resorptionnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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through the inhibition of receptor activator of nuclear factor kappa-
B ligand (RANKL)-induced osteoclast differentiation in RAW cells
(5) and osteoclastic bone resorption in vitro (6). Local injection of
MPMBP inhibits alveolar bone resorption in rats with experimental
periodontitis (7). Furthermore, administration of MPMBP has been
shown to prevent rat adjuvant arthritis, possibly through a
decrease in inﬂammatory molecules and other factors, such as tu-
mor necrosis factor (TNF)-a, neutrophil chemoattractant-1, inter-
leukin (IL)-1-like activity, and serum sialic acid (8,9). MPMBP also
prevents lipopolysaccharide-stimulated increases in prostaglandin
(PG) E2 production in organ cultures of neonatal mouse calvaria (7)
and IL-1b production in macrophage-like cells (10).
In the current study, we investigated whether MPMBP could
increase bone mass in post-ovariectomy (OVX) rats, and if so, to
gain understanding of the underlying mechanism.
2. Materials and methods
2.1. MPMBP synthesis
MPMBPwassynthesized in three steps (Fig.1A)basedonTsuruta's
procedure (11). Brieﬂy, tetraisopropyl (4-methylthiophenylthio)
methanediphosphonate was prepared from commercially available
tetraisopropyl methylenediphosphonate and bis[4-(methylthio)
phenyl] disulﬁde, the latter of which was prepared as described
previously (12), in the presence of tert-BuOK with 61% yield. The
tetraisopropyl ester was then hydrolyzed with concentrated HCl and
treated with sodium bicarbonate to yield the target MPMBP in two
steps.
The reaction progress was monitored using thin-layer chroma-
tography on Merck Art. 5715 Kieselgel 60 F254/0.25-mm thickness
plates, and was visualized using UV light, iodine vapor, and cerium
sulfateeammonium molybdate solution followed by heating. 1H
and 13C nuclear magnetic resonance (NMR) spectra were recorded
using a JEOL JNM AL-400 instrument (JEOL Ltd., Akishima, Japan)
(400 MHz for 1H and 100 MHz for 13C) in deuterated solvent; tet-
ramethylsilane (d ¼ 0.0 ppm in 1H NMR spectra) and CDCl3
(d ¼ 77.0 ppm in 13C NMR spectra) were used as internal standards.
High-resolution mass spectra (HRMS) were obtained using a JEOL
JMS-MS700V (JEOL Ltd., Akishima, Japan) with p-nitrobenzyl
alcohol as the matrix.
2.2. Preparation of MPMBP for injection
The pH of the injection solution was adjusted to 7.4 with HCl or
NaOH, as appropriate. The osmolality was adjusted to 310 mOsm
with NaCl in water. All solutions were sterilized by ﬁltration (Mil-
lex-GV, PVDF, 0.22-mm pore, Millipore, MA, USA).
2.3. Animals and experimental schedule
Seventy 12-week-old female virgin SpragueeDawley rats were
purchased from Kumagai-Shigeyasu Co. Ltd. (Sendai, Japan). Fifty
rats underwent OVX and 20 were subjected to a sham-OVX oper-
ation (sham); the operations were performed by Japan SLC, Inc.
(Hamamatsu, Japan) (Fig. 2A, B). Rats that underwent an operation
at Japan SLC were housed at 22e25 C under a 12-h light/dark cycle
in speciﬁc pathogen-free (SPF) conditions, and were fed a rodent
diet (MF, Oriental Yeast Co., Ltd.) and water ad libitum. During the
experimental period, two or three rats were housed together in the
same cage (355  405  230 (W  D  H (mm)), TECNIPLAST GR-
900SEAL SAFEPLUS, Mevaseret Zion, Israel) which weremaintained
by an individually ventilated cage system. Animal care and exper-
iments were performed in accordance with the guidelines of theInstitute for Animal Experimentation of Tohoku University Grad-
uate School of Medicine. The Animal Research Committee of
Tohoku University approved the study protocol, and the Committee
for Animal Experiments at Japan SLC Inc. approved the ovariectomy
protocol.
Twelve weeks after the operations, 10 rats from each of the OVX
and sham groups were sacriﬁced to conﬁrm whether OVX had
induced osteopenia (Fig. 2A). The remaining 40 OVX rats were
divided into four groups of 10 animals each and treated with
MPMBP (1.2, 6.0, or 30 mg/kg) or 0.9% NaCl subcutaneously once
per week for 12 weeks. The remaining sham rats (n ¼ 10) were
maintained under the same conditions without injection (Fig. 2B).
The MPMBP dose for this experiment was chosen in reference to
our previous preliminary experiment (7).
The bodyweight of the animals was measured once per week
during the 24-week experimental period. At the end of the exper-
iment, both tibiae of all animals were dissected for subsequent
analyses.
To determine bone formation, the rats were sequentially labeled
as follows: 1 day ON- 45 days OFF- 1 day ON- 45 days OFF- 1 day
ON- 1 day OFF (1-45-1-45-1-1), prior to necropsy. Tetracycline
hydrochloride (30 mg/kg, Wako Pure Chemical Industries, Osaka,
Japan) or calcein (40 mg/kg, Dojin Chem., Kumamoto, Japan) were
administered.
2.4. Micro-computed tomography (micro-CT)
CT images of the right proximal tibial metaphysis were obtained
using a micro-CT scanner (La Theta LCT200; Aloka, Tokyo, Japan)
according to the manufacturer's protocol. Cancellous bone mineral
density (BMD), cortical BMD, total BMD, minimum second moment
of area, and polar moment were calculated automatically using
software. Cancellous bone volume was calculated from the term
“trabecular volume”, as deﬁned by the software, which deﬁnes
cancellous volume excluding bone marrow volume. Total bone
volume was calculated from the term “sub-total volume”, as
deﬁned by the software, which refers to the volume of cortical and
trabecular bone.
Three-dimensional (3D) data were obtained by constructing
sliced images along the Z-axis and were analyzed using an image
analyzer (VGStudio MAX software; Volume Graphics, Heidelberg,
Germany). The scanner was calibrated prior to each scanning pro-
cedure using hydroxyapatite as a calibration phantom, which has a
known BMD, manufactured by Kyoto Kagaku Co., Ltd. (Kyoto,
Japan).
2.5. Hematoxylin and eosin staining and immunohistochemistry
The left tibiae were ﬁxed in 4% paraformaldehyde, decalciﬁed in
10% EDTA, and then embedded in parafﬁn. Frontal sections (3-mm-
thick) were subjected to hematoxylin and eosin (H&E) staining or
immunohistochemistry.
For type I collagen, sections were blocked with 5% skimmed
milk in phosphate buffered saline (PBS), prior to incubation with
rabbit anti-type I collagen polyclonal antibodies (LSL, Cosmo Bio Co.
Ltd., Tokyo, Japan). Sections were then washed with PBS and
incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG
(H þ L) (1:1000 dilution, Life Technologies, Carlsbad, CA, USA) and
0.1 mg/ml DAPI (Dojin Laboratories, Kumamoto, Japan) for 1 h at
room temperature. Sections were thenwashed in PBS andmounted
in glycerin in PBS. Images were acquired using a ﬂuorescence mi-
croscope (Biorevo, BZ-9000; Keyence, Tokyo, Japan).
For cathepsin K localization, sections were subjected to antigen
retrieval by immersion in 0.01 M citrate buffer at 100 C, pH 6.0,
followed by heating in a microwave oven (Sharp, Osaka, Japan) at
Fig. 1. Synthesis of MPMBP. (A) Three steps of MPMBP synthesis. (BeD) The 1H NMR spectra and 13C NMR spectra: chemical shift (d in ppm), multiplicity (s ¼ singlet,
d ¼ doublet, t ¼ triplet, q ¼ quartet, m ¼ multiplet), and coupling constant (J in Hz), respectively. (B) In step 1, bis[4-(methylthio)phenyl] disulﬁde (217 mg, 92%) was obtained as a
white solid; 1H NMR (400 MHz, CDCl3) d 7.39 (d, J ¼ 8.5 Hz, 4H), 7.17 (d, J ¼ 8.5 Hz, 4H), 2.46 (s, 6H); 13C NMR (100 MHz, CDCl3) d 138.6, 133.4, 129.4, 126.9, 15.7; HR-FAB MS calcd for
C14H14S4 [M]þ 309.9978, found 310.0003. (C) In step 2, tetraisopropyl (4-methylthiophenylthio) methanediphosphonate (185 mg, 61%) was obtained as a colorless oil, as shown in
Fig. 1C; 1H NMR (400 MHz, CDCl3) d 7.54 (d, J ¼ 8.5 Hz, 2H), 7.17 (d, J ¼ 8.5 Hz, 2H), 4.90e4.81 (m, 4H), 3.23 (t, J ¼ 21.7 Hz, 1H), 2.46 (s, 3H), 1.35 (d, J ¼ 6.1 Hz, 24H); 13C NMR
(100 MHz, CDCl3) d 138.7, 132.3, 131.8, 126.7, 72.4 (dt, J ¼ 10.8, 3.3 Hz), 44.1 (t, J ¼ 139.9 Hz), 24.0 (dq, J ¼ 42.2, 1.7 Hz), 15.6; HR-FAB MS calcd for C20H37O6P2S2 [MþH]þ 499.1507,
found 499.1550. (D) Finally, the residue of step 3 was recrystallized from H2O/ethanol to yield sodium salt (950 mg, 89%) as a white solid; 1H NMR (400 MHz, D2O) d 7.39 (d,
J ¼ 8.5 Hz, 2H), 7.17 (d, J ¼ 8.5 Hz, 2H), 3.05 (t, J ¼ 18.5 Hz, 1H), 2.38 (s, 3H); 13C NMR (100 MHz, D2O) d 136.3, 136.1, 131.3, 128.1, 44.6 (t, J ¼ 111.3 Hz), 16.0; HR-FAB MS calcd for
C8H11Na2O6P2S2 [M þ H]þ 374.9268, found 374.9297.
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Fig. 2. Bodyweight during experiment. A, B; Experimental schedule. Twelve-week-old female SpragueeDawley rats were subjected to ovariectomy (OVX). Closed and open red
arrowheads indicate the timing of OVX (n¼ 50) and sham operations (Sham op.; n¼ 20), respectively. Animals in experiment Awere used for the analysis of the effects of OVX. Twelve
weeks after OVX, a subset of Sham (n¼ 10) and OVX (n¼ 10) ratswere sacriﬁced to determinewhether OVX had induced osteopenia. Animals in experiment Bwere used for analysis of
the effects of MPMBP. The 40 OVX rats were divided into four groups and treated with the indicated doses of MPMBP subcutaneously (0, 1.2, 6.0, and 30 mg/kg, n¼ 10 per group) once
per week for 3months. For sequential labeling to determine bone formation, rats were labeled as follows: 1 day ON- 45 days OFF- 1 day ON- 45 days OFF- 1 day ON- 1 day OFF, prior to
necropsy (1-45-1-45-1-1). A subcutaneous injection of 30mg/kg of tetracycline hydrochloride (TC; yellow arrow) was administered both at the ﬁrst MPMBP administration and 1 day
before sacriﬁce. Rats were also labeled with 40mg/kg of calcein (CL; green arrow) at the midpoint of MPMBP administration. To investigate bone formation in adult rats, wemeasured
the distance between the ﬂuorescently-labeled lines by long interval ﬂuorescein to analyze themetabolic rate of trabecular bone in themetaphysis and cortical bone in diaphysis. C, D;
Bodyweight. (C)Mean bodyweights of rats that received anovariectomy (OVX, n¼ 50) or shamoperation (Sham, n¼ 20) from12 to 24weeks of age. *p< 0.05; ShamvsOVXby repeated
measure ANOVA and #p< 0.05; Shamvs OVX by student t-test. (D)Mean bodyweights of rats that receivedOVX and the subcutaneous administration of 0.9% NaCl (OVXþ 0, n¼ 10), or
1.2, 6.0 and 30 mg/kg/week MPMBP (OVX þ 1.2, OVX þ 6.0 and OVX þ 30, respectively; n ¼ 10 per group), and of rats that received a sham operation (Sham, n ¼ 10) from 24- to 36-
weeks-of-age. All values are expressed asmeans. *p< 0.05; ShamvsOVXþ 0, OVXþ 1.2 or OVXþ 6.0 by repeatedmeasure ANOVA, #p< 0.05; ShamvsOVXþ 0, OVXþ 1.2, OVXþ 6.0 or
OVX þ 30 by TukeyeKramer HSD test, and bp < 0.05; Sham vs OVX þ 0, OVX þ 1.2 or OVX þ 6.0 by TukeyeKramer HSD test.
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for 20min, washed in PBS for 5min, and incubatedwith rabbit anti-
cathepsin K polyclonal antibodies (1:200 dilution, Abcam Inc.,
Cambridge, MA, USA) for 2 h at room temperature. After washing,
endogenous peroxidase was blocked with methanol containing
0.3% hydrogen peroxide for 20 min at room temperature before
being washed again in PBS, incubated with Simple Stain Rat MAX-
PO (R) (Nichirei Biosciences, Tokyo, Japan) for 30 min, and washed
with PBS. The signal was developed using diaminobenzidine (DAB)
Histoﬁne SAB-PO (M) (Nichirei Biosciences, Tokyo, Japan) solution
for 20 min at room temperature. After washing, the sections were
counterstained with hematoxylin and mounted with VectaMount
Mounting Medium (Vector Laboratories, Inc., Burlingame, CA, USA).
Control samples were treated with the same concentration of non-
immune rabbit serum as a negative control. Images of uniform
ﬁelds (720  520 mm) of the primary trabeculae were acquired
at 20 magniﬁcation using a light microscope (Biorevo, BZ-9000;
Keyence, Tokyo, Japan).
Cathepsin K is an osteoclast-speciﬁc cysteine protease involved
in osteoclast function and bone resorption via the cleavage of type I
collagen (13) and, similar to tartrate-resistant acid phosphatase
(TRAP), is expressed in both resorbing and non-resorbing osteo-
clasts, but differs from TRAP by not being expressed in prefusion
osteoclasts (14,15) Numbers of cathepsin K-positive multinuclear
giant cells in resorption lacunae or on the bone surface that had
more than three nuclei were counted as osteoclasts. Furthermore,
numbers of cathepsin K-positive cells, which were detached from
bone surface, were also counted. Bone surface measurements were
performed using open-source ImageJ software (16).
2.6. Measurements of bone marrow adipocytes
The adipocyte number (/mm2), percentage adipocyte area per
tissue area (%), and mean adipocyte diameter (mm) were quantiﬁed
using sections of the left tibiae stained with H&E. Adipocytes were
recognized as distinct, translucent ellipsoids and color-labeled in all
of the ﬁelds analyzed. Measurements were performed using open-
source ImageJ software.
2.7. Sequential labeling for bone formation with tetracycline and
calcein
The right tibiae were ﬁxed with 70% ethanol, stained with
Villanueva-Goldner bone stain (Wako Pure Chemical Industries
Ltd., Osaka, Japan) for 7 days, and then embedded in methyl
methacrylate (MMA) without decalciﬁcation, according to the
manufacturer's instructions (Osteoresin Embedding Kit; Wako,
Osaka, Japan). Frontal (Fig. 6A) or cross (Fig. 8A) sections were
prepared using a low-speed diamondwheel saw (model 650, South
Bay Technology Inc., San Clemente, CA, USA). The resulting samples
were mounted on a ﬂuorescence microscope and connecting im-
ages were acquired (BZ-9000; Keyence, Tokyo, Japan). Lines of bone
labeled ﬂuorescently with tetracycline (yellow) and calcein (green)
were analyzed.
2.8. Statistical analysis
Statistical analyses were performed using the student t-test for
comparison between two groups (Fig. 3C) or one-way analysis of
variance (ANOVA) for comparison among all ﬁve groups. The
TukeyeKramer HSD (honestly signiﬁcant difference) test was used
for post hoc pair-wise comparisons. Results are presented as
means ± standard deviation (SD). All statistical analyses were
performed using JMP Pro software (version 11, SAS Institute Inc.,Cary, NC, USA). All values are expressed as means ± SD. *p < 0.05,
**p < 0.01, ***p < 0.001.
3. Results
3.1. MPMBP synthesis
MPMBP was synthesized in three steps (Fig. 1A) based on
Tsuruta's procedure (11). The 1H and 13C NMR spectral data
demonstrated that the isolated MPMBP by recrystallization was
pure (Fig. 1BeD). The molecular weight of MPMBP was 374.2091.
3.2. Bodyweight
The bodyweight of all rats increased after the operation. Rats
were then purchased and shipped. The weight of all rats continued
to increase for the two weeks following shipping, with OVX rats
showing a signiﬁcant increase in bodyweight compared with sham
rats (Fig. 2C).
Twenty rats were necropsied to conﬁrm the effects of OVX
(Fig. 2A), and the remaining 50 24-week-old rats were used in
experiments to assess the effects of MPMBP (Fig. 2B). Mean body-
weight of the OVX rats was more than 50 g higher than that of the
sham rats. The weight of rats treated with 30 mg/kg MPMBP
decreased slightly from 5 weeks after treatment for unknown
reasons, but increased in a similar manner to rats in the sham group
(Fig. 2D).
3.3. Effects of OVX on tibial bone
OVX induced severe osteopenia. Trabecular bone size in OVX
rats was markedly decreased and bones were more porous than
those from sham rats. In contrast, cortical bones were comparable
between OVX and sham rats. Fig. 3A shows images of the proximal
tibia 12 weeks after OVX.
Micro-CT analysis revealed that BMD and bone volume of the
cancellous bone, and BMD of the cortical bone, were signiﬁcantly
decreased in OVX rats, whereas bone volume of the cortical bone
was unchanged. The total bone parameters, which combined data
from cancellous and cortical bone, were also decreased in OVX rats.
Additionally, the minimum second moment of area, a parameter of
bending strength, and the polar moment of inertia, a parameter of
torsional strength, were decreased in OVX rats (Fig. 3C).
Histological analysis (Fig. 3DeF) revealed that OVX resulted in a
larger marrow space and less trabecular bone compared with the
sham rats. The trabecular bone architecture had also disappeared
(Fig. 3E), and many marrow adipocytes appeared as distinct,
translucent ellipsoids in the marrow cavity. In the sham rats, only a
small number of marrow adipocytes were embedded in bone
marrowmononuclear cells among the trabecular bone architecture
(Fig. 3F).
3.4. Effects of MPMBP on bone loss and impaired mechanical
properties in OVX rats
Micro-CT revealed that bone loss in OVX rats was increased by
MPMBP treatment in a dose-dependent manner, compared with
untreated OVX rats. In contrast, the cortical bones of OVX rats
were comparable to those from sham rats (Fig. 4A). Fig. 4B shows
the micro-CT parameter analysis results. BMD and volume of
both the cancellous and total bone, and volume of the cortical
bone, increased following administration of MPMBP. The mini-
mum second moment of area and the polar moment of inertia
were also increased in a dose-dependent manner following
treatment with MPMBP. In contrast, there was no signiﬁcant
Fig. 3. Micro-CT analysis and histological evaluation of the effects of ovariectomy. (A) Micro-CT images of the proximal tibia of sham operated (Sham) and ovariectomized (OVX)
rats 12 weeks after OVX. The trabecular bone mass of OVX rats was markedly decreased and was more porous compared with that in the Sham rats. In contrast, the cortical bone
mass of OVX rats was comparable to those in the Sham rats. (B) Analyzed voxel of interest (VOI); CT scans were performed from the proximal to distal with a 24  24  96-mmvoxel
resolution at 50 kV and 0.5 mA. To assess the metaphyseal region, a total of 120 scanning image slices were taken from one tibia, and the ﬁrst 21 slices (approximately 2.0 mm) distal
to the junction of growth cartilage with the metaphysis were used for subsequent analyses. (C) Measured bone parameters included: bone mineral density (BMD), bone volume,
minimum second moment of area (a parameter of bending strength), and polar moment of inertia (a parameter of torsional strength). All values are expressed as means ± SD.
*p < 0.05 by student t-test. (D) Hematoxylin and eosin (H&E) staining of the proximal metaphysis of the tibia, (E) enlarged images of the growth plate and the primary spongiosa
(PS), and (F) bone marrow adipocytes in the secondary spongiosa.
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(Fig. 4B), which reﬂects the similar structure as assessed by mi-
cro-CT.
3.5. Effects of MPMBP on bone marrow adipogenesis in OVX rats
Histological observations using H&E staining in OVX rats
revealed larger bone marrow cavities and less trabecular bone
compared with the sham rats (Fig. 5A). The administration of
MPMBP to OVX rats was associated with an observed increase in
trabecular bone in the bone marrow cavities in these animals. In
addition, compact plate-like structures of primary spongiosa (PS)
were formed in MPMBP-treated rats and the invasion of bone
marrow tissue into the hypertrophic cartilage was inhibited in a
dose-dependent manner (Fig. 5B). The increased number of bone
marrow adipocytes in OVX rats was signiﬁcantly reduced following
treatment with MPMBP (Fig. 5C), whereas the reduction of
trabecular bone volumewas restored. The number, size, and area of
adipocytes in themarrow cavities were decreased to the levels seen
in sham rats following treatment with 30 mg/kg/week of MPMBP
(Fig. 5D).
3.6. Effects of MPMBP on endochondral ossiﬁcation in the
metaphysis
Longitudinal growth of the PS was signiﬁcantly decreased by
MPMBP treatment (Fig. 6B, C). However, ﬂuorescence labeled
tetracycline and calcein lines became more intense and compact
following the administration ofMPMBP (Fig. 6B; OVXþ 1.2, 6.0, 30).
3.7. Effects of MPMBP on the expression of type I collagen in the PS
Immuno-reactive type I collagen was present in bone-surface
osteoblasts and accumulated along the surface of the trabecular
bone, but was not observed in the growth plate cartilage of sham
rats (Fig. 7A; Sham). OVX reduced the number, longitudinal length
and transverse connection of trabecular bones, and showed weak
type I collagen immunoreactivity at the thin osteoid and
osteoblast-like cells subjacent to the growth plate (Fig. 7A;
OVX þ 0). Although bone marrow tissue invaded near the growth
plate cartilage in the sham and OVX rats, the invasion of marrow
cells into the hypertrophic cartilage was blocked following treat-
ment with MPMBP. Furthermore, a remarkable increase in type I
collagen expressionwas observed in osteoblasts and the osteoid, as
well as in longitudinally extending trabecular bones from the PS
(Fig. 7A; OVX þ 1.2 and OVX þ 6.0). Type I collagen was localized
not only on the surface of the calciﬁed cartilage, which was eroded
by chondroclasts, but also in the entire PS from the subjacent
growth plate after the administration of 30 mg/kg/week MPMBP
(Fig. 7A; OVX þ 30).
3.8. Effects of MPMBP on the number of cathepsin K-positive cells
Cathepsin K-positive multinucleated bone resorbing osteoclasts
were observed in the subchondral trabecular bone in the sham rats
(Fig. 7B; Sham). OVX increased the number of bone resorbing
cathepsin K-positive cells per both bone area and bone surface
(Fig. 7D; OVX þ 0). However, the number of bone resorbing
cathepsin K-positive osteoclasts signiﬁcantly decreased following
administration of MPMBP (Fig. 7D; OVX þ 1.2, OVX þ 6.0 and
OVX þ 30) in a dose-dependent manner. Furthermore, many small
cathepsin K-positive cells, which had detached from the bone
surface, were observed in the subchondral compact plate-like
structure of the PS in the OVX þ 30 group. These cells weresigniﬁcantly increased following administration of MPMBP in a
dose-dependent manner (Fig. 7E).
3.9. Effects of MPMBP on endosteal ossiﬁcation in the tibial
diaphysis
There was no signiﬁcant difference between the sham and OVX
rats with respect to the width between the ﬂuorescent-labeled
tetracycline lines in the endosteal region. However this was
notably and signiﬁcantly increased after treatment with 1.2 mg/kg/
week MPMBP. In addition, the area between the ﬂuorescent-
labeled lines was signiﬁcantly increased following treatment with
1.2 and 30 mg/kg/week MPMBP (Fig. 8C).
BMD and bone volume of cortical bone were signiﬁcantly
increased following treatment with 1.2 mg/kg/week MPMBP as
determined by micro-CT analysis (Fig. 8E).
4. Discussion
In the present study, we initiated administration ofMPMBP after
conﬁrmation that OVX had induced bone loss in rats, to determine
whether MPMBP could elicit a curative effect on bone loss. We
assessed the effect of MPMBP on bonemass and density in OVX rats
using micro-CT. The result showed that systemic MPMBP signiﬁ-
cantly improved trabecular bone mass and density. The National
Institutes of Health consensus statement deﬁnes osteoporosis as a
skeletal disorder characterized by compromised bone strength that
predisposes a person to an increased risk of fracture (17). We
therefore assessed the effect of MPMBP on the mechanical prop-
erties of bone, such as the second moment of area, an indicator of
bending strength, and the polar moment of inertia, an indicator of
torsional strength. As a result, both mechanical property parame-
ters increased following administration of MPMBP. The results
indicated that MPMBP improved not only bone mass and BMD, but
also the quality of bone.
To clarify the mechanism of improved BMD, we investigated the
effects ofMPMBP on bone resorption and bone formation. Similar to
other BPs, MPMBP inhibits osteoclastogenesis in vitro (5,6) and re-
duces alveolar bone resorption in periodontitis (7). In the present
study, the number of cathepsin K-positive bone resorbing osteo-
clasts,whichweremultinucleated and existed in resorption lacunae,
signiﬁcantly decreased following MPMBP administration (Fig.7D),
suggesting that systemic administration of MPMBP inhibits osteo-
clastic bone resorption in vivo. In contrast, the number of cathepsin
K-positive cells, which were detached from the bone surface in the
PS, signiﬁcantly increased following MPMBP (Fig. 7E). However
these cathepsin K-positive cells appeared non-functional, because
their features looked abnormal (round-shape, loss of polarity and
detached from thebone surface). Similar phenomenawereobserved
after the administration of nitrogen-containing BPs (18).
MPMBP is reported to have anti-oxidative (6) and anti-
inﬂammatory (7e10) actions, and suppresses the production of
inﬂammatory molecules such as IL-1, IL-6, TNF-a, macrophage
colony-stimulating factor, and PGs (19e22). These inﬂammatory
cytokines are known to increase in estrogen-deﬁciency and result
in increased bone resorption via an increased RANKL/osteoprote-
gerin ratio (23). In fact, IL-1 or TNF-a blockers suppress the rise in
bone resorption markers in early postmenopausal females (24).
Since MPMBP suppresses production of the above cytokines, it is
probable that the anti-inﬂammatory action of MPMBP might be
involved in the mechanism of inhibition of bone resorption in the
present OVX-induced osteopenia.
Fluorescent bone mineral labeling was performed to determine
the effect of MPMBP on bone formation. Endochondral ossiﬁcation
of the metaphysis consists of coordinated osteoclastic bone
Fig. 4. Micro-CT analysis of tibia after treatment with MPMBP. (A) Micro-CT images of the proximal tibia of sham operated (Sham, n ¼ 10), and ovariectomized (OVX) rats
administered 0.9% NaCl (OVX þ 0, n ¼ 10), or 1.2, 6.0 and 30 mg/kg/week MPMBP (OVX þ 1.2, OVX þ 6.0 and OVX þ 30, respectively; n ¼ 10 per group) for 12 weeks. The trabecular
bone mass and density of OVX rats increased following administration of MPMBP. A more dense bone structure was observed at the growth plate. (B) Bone parameters measured
using micro-CT included: bone mineral density (BMD), bone volume, minimum second moment of area (a parameter of bending strength), and polar moment of inertia (a parameter
of torsional strength). Of the parameters measured, cancellous and total bone mass and density increased following the administration of MPMBP in a dose-dependent manner,
whereas cortical bone BMD did not. The minimum second moment of area and the polar moment of inertia were also increased following the administration of MPMBP. All values
are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA and TukeyeKramer HSD test.
Fig. 5. Histological observation of the effects of MPMBP. (A) Hematoxylin and eosin (H&E) staining of the proximal metaphysis of the tibia, (B) enlarged images of the growth
plate (GP) and primary spongiosa (PS), and (C) bone marrow adipocytes in secondary spongiosa. Sham: sham operated, OVX þ 0: ovariectomized rats with subcutaneous
administration of 0.9% NaCl (0 mg/kg/week MPMBP), OVX þ 1.2, OVX þ 6.0 and OVX þ 30: ovariectomized rats with the subcutaneous administration of 1.2, 6.0 and 30 mg/kg/week
MPMBP, respectively. (D) Four randomly selected images of uniform ﬁelds (180  130 mm) of secondary spongiosa (excluding the bone trabecule) in the marrow cavity were
acquired at 20 magniﬁcation using a light microscope. The adipocyte number (/mm2), percentage adipocyte area per tissue area (%), and mean adipocyte diameter (mm) were
quantiﬁed using sections of the left tibiae stained with H&E. Adipocytes were recognized as distinct, translucent ellipsoids and color-labeled in all ﬁelds analyzed. Measurements
were performed using open-source ImageJ software. All parameters were signiﬁcantly decreased by treatment with MPMBP in OVX rats. All values are expressed as means ± SD.
*p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA and TukeyeKramer HSD test (groups: n ¼ 6).
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Fig. 6. Fluorochrome labeling to identify longitudinal endochondral ossiﬁcation in the growth plate. (A) Standardized sample preparation for analysis. Frontal sections were
prepared from the proximal tibia. (B) Section images for each group. Three ﬂuorescently labeled lines of tetracycline (yellow circles), calcein (white circles) and tetracycline (yellow
circles) were observed. Sham: sham operated; OVX þ 0: ovariectomized rats administered 0.9% NaCl (0 mg/kg/week MPMBP); OVX þ 1.2, OVX þ 6.0 and OVX þ 30: ovariectomized
rats administered 1.2, 6.0 and 30 mg/kg/week MPMBP, respectively. Enlarged OVX þ 30 image. Double ﬂuorescent lines were observed following ﬁrst tetracycline (indicated as two
yellow circles) and second calcein (indicated as two white circles) labeling in the OVX þ 30 mg/kg administration group. (C) Distance (mm) between the ﬁrst and third sequentially
tetracycline-labeled lines (distance between the red arrows) during endochondral ossiﬁcation. All values are expressed as means ± SD. Labeled lines in OVXþ0 rats were detected
intermittently and were insufﬁcient for analysis (ND). *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA and TukeyeKramer HSD test (groups: n ¼ 10).
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the growth plate (25). Our results showed that longitudinal ossiﬁ-
cation decreased following MPMBP treatment, as demonstrated by
the distance between labeled lines of tetracycline and calcein.
However, longitudinal width of compact bone-like structure was
increased in the PS (Figs. 5B and 7A), suggesting that new bone
formation may have increased in the transverse direction to form a
compact bone-like structure. These structures may have contrib-
uted to improved trabecular bone density and bone strength as
revealed by the micro-CT analysis.
In addition, mineral apposition rate in the endosteal bone sur-
face in the tibial diaphysis (Fig. 8C) increased in the transverse cross
section, suggesting that endosteal new bone formation increased
following MPMBP administration.It is reported that the mineral apposition rate in the tibial shaft
was increased in OVX-rats 1 month after the OVX-operation (26). In
this study, the same tendency was observed 3 months after the
OVX-operation (Fig. 8C, Sham vs OVX þ 0), although the increase
was not statistically signiﬁcant, probably due to differences in the
period after OVX-operation. However, the effects of MPMBP at
doses of 1.2 and 6.0 mg/kg/week on bone formation were clearly
beyond the effects of OVX itself (Fig. 8C).
Type I collagen is a major bone matrix component distributed in
90% of bone, and is secreted by osteoblasts during bone formation
(27). Interestingly, type I collagen was abundant not only at the
surface of the calciﬁed cartilage eroded by chondroclasts, but also in
the entire PS subjacent to the growth plate following administration
of 30 mg/kg/week MPMBP (Fig. 7A OVX þ 30), suggesting that
Fig. 7. Effect of MPMBP on type I collagen expression and cathepsin K-positive osteoclasts. (A) The proximal metaphysis of the right tibiae were stained with rabbit anti-type I
collagen polyclonal antibodies and Alexa Fluor 488 (green)-conjugated goat anti-rabbit IgG (H þ L). DAPI (blue) was used to stain the nuclei. Sham: sham operated, OVX þ 0:
ovariectomized rats administered 0.9% NaCl (0 mg/kg/week MPMBP), OVX þ 1.2, OVX þ 6.0, and OVX þ 30: ovariectomized rats administered 1.2, 6.0, and 30 mg/kg/week MPMBP,
respectively. Growth plate cartilage (GP) showed no immunoreactivity for type I collagen. The longitudinal lengths of the primary spongiosa (PS) were increased following
treatment with MPMBP. The bottom of the hypertrophic cartilage layer in OVX þ 30 exhibited intense expression of type I collagen. (B) Cathepsin K immunostaining was performed.
Brown multinucleated bone-resorbing osteoclasts (white arrowhead) were observed in the subchondral trabecular bone. Sham: sham operated, OVX þ 0: ovariectomized rats with
the subcutaneous administration of 0.9% NaCl (0 mg/kg/week MPMBP), OVX þ 1.2, OVX þ 6.0, and OVX þ 30: ovariectomized rats with the subcutaneous administration of 1.2, 6.0,
and 30 mg/kg/week MPMBP, respectively. (C) Many cathepsin K-positive cells, which had detached from the bone surface, (black arrowhead) were observed in the subchondral
compact plate-like structure of the primary spongiosa in rats administrated 30 mg/kg/week MPMBP (OVX þ 30). (D) Number of osteoclasts. The number of bone resorbing cathepsin
K-positive osteoclasts, which were multinucleated, and existed in resorption lacunae, per both area and bone surface signiﬁcantly decreased after treatment with MPMBP in OVX
rats. (E) Number of cathepsin K-positive cells detached from the bone surface. All values are expressed as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA and
TukeyeKramer HSD test (groups: n ¼ 6).
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Fig. 8. Effect of MPMBP on endosteal and periosteal ossiﬁcation in cross-sections of cortical bone. (A) Standardized sample preparation for analysis. After measuring the
longitudinal full tibia length, one-third of the proximal tibia was cut in transverse plane. (B) Images of transverse cross-sections for each group. Three ﬂuorescently labeled lines of
tetracycline (yellow arrowhead), calcein (white arrowhead), and tetracycline (yellow arrowhead) were observed. Sham: sham operated, OVX þ 0: ovariectomized rats with the
subcutaneous administration of 0.9% NaCl (0 mg/kg/week MPMBP), OVX þ 1.2, OVX þ 6.0, and OVX þ 30: ovariectomized rats with the subcutaneous administration of 1.2, 6.0, and
30 mg/kg/week MPMBP, respectively. (C) Distance (mm) between the ﬁrst and third sequentially tetracycline-labeled lines (distance between the red arrows) during the endosteal
ossiﬁcation. (D) Area (mm2) within the outline formed by the ﬁrst and third labeled lines in both the endosteal and periosteal ossiﬁcation. (E) Analyzed VOI; To assess cortical bone in
the diaphysis region, CT scans were performed from distal to proximal initiating at the one-third transverse plane of longitudinal full length with a 24 24 96-mmvoxel resolution
at 50 kV and 0.5 mA. A total of 20 scanning image slices were taken from one tibia, and the ﬁrst 11 slices (approximately 1.0 mm) were used for subsequent analyses. This VOI
included the same transverse plane observed in (B). (F) BMD and the volume of cortical bone signiﬁcantly increased with the treatment of 1.2 mg/kg/week. All values are expressed
as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA and TukeyeKramer HSD test (groups: n ¼ 10).
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lation occurred at this site. However, it is unclear whether the
accumulation of type I collagen could be attributed to enhanced
synthesis in situ or was simply exempt from osteoclastic bone
resorption. If attributable to the former, hypertrophic chondrocytes
or mesenchymal stem cells (MSCs) subjacent to the growth plate
may have differentiated into osteoblast lineage cells and facilitated
the synthesis of type I collagen following treatment with MPMBP.
Recently, evidence for the transdifferentiation of hypertrophic
chondrocytes to osteoblasts has been reported (28,29). However it is
not yet knownwhether the increase of type I collagen accumulation
in endochondral ossiﬁcation by MPMBP is associated with this
transdifferentiation of hypertrophic chondrocytes to osteoblasts.
Notably, endosteal new bone ossiﬁcation in the diaphysis was
not inhibited, and was indeed stimulated after MPMBP treatment
(1.2 or 6.0 mg/kg/week) (Fig. 8). There is a consensus that the
common effect of BPs is through inhibition of osteoclastic bone
resorption (30). MPMBP also decreased the number of osteoclasts
dose-dependently in this study. In humans, BPs inhibit bone for-
mation with an observable decrease in bone formation markers
(31). However, our results indicate that MPMBP may have stimu-
latory effects on bone formation. Thus, further investigation is
needed to clarify the alterations in osteoblast markers caused by
treatment with MPMBP in vivo and in vitro.
Previous studies suggest that other BPs, such as alendronate
(32), risedronate (32), pamidronate (32), zoledronate (33), and
clodronate (34), have anabolic effects in vitro. Although the precise
mechanisms or molecular pathways of enhanced osteoblast pro-
liferation, differentiation and activation are unclear, upregulation of
bone morphogenetic protein-2 (32), the anti-apoptotic effect of
Connexin 43 hemichannels (35), and inhibition of MSC adipogenic
differentiation (36,37), have all been considered.
With focus on bone marrow adipocytes in this study, results
from H&E-stained specimens demonstrated that the observed in-
crease in bone marrow adipogenesis in OVX rats was signiﬁcantly
inhibited by administration of MPMBP. Since osteoblasts and bone
marrow adipocytes are derived from the same bone marrow MSCs
(38e40), it is conceivable that bone metabolism is regulated by the
balance between adipogenesis and osteogenesis. While a similar
adipogenesis inhibitory action has been reported for nitrogen-
containing BPs, such as alendronate (31), risedronate (31), and
zoledronate (41), there have been no published reports on a non-
nitrogen-containing BP, including MPMBP.
Unfavorable actions of adipocytes on osteoporosis have been
reported. For example, saturated fatty acids secreted by adipocytes
inhibit osteoblast activity (42), whilst adipocyte-rich bone marrow
supernatant ﬂuid from osteoporotic women has a high concentra-
tion of pro-inﬂammatory cytokines (43). Furthermore, marrow
adipocytes express RANKL, which promotes osteoclastogenesis
(44). Evidence for a potential role of reactive oxygen species (ROS)
has been reported, whereby elevated levels of ROS promote adi-
pogenesis but inhibit MSC osteogenic differentiation (45). Since
MPMBP has anti-oxidative and anti-inﬂammatory actions, MPMBP
might contribute to the inhibition of adipogenesis and the induc-
tion of osteogenesis in OVX-rats.5. Conclusions
In conclusion, systemic MPMBP treatment increased bone mass
and BMD, and improved the mechanical strength of osteoporotic
bone. Both inhibition of bone resorption and stimulation of bone
formation might be involved in the mechanism of MPMBP action.
Our ﬁndings suggest that MPMBP may be useful for treating bone
loss induced by estrogen deﬁciency.Conﬂict of interest
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